ClinicalTrials.gg
Status unknownNCT03278717ICON9Updated Sep 27, 2022

Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients

A Phase 3 interventional study of Olaparib and Cediranib in Ovarian Cancer, sponsored by University College, London. Status unknown at 54 sites in 4 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-27.

Sponsored by University College, London · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jun 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
330
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 16 studies testing cediranib in Ovarian Neoplasms — none open to participants now, 3 under way, 2 of them phase 3. cediranib · Ovarian Neoplasms.

Planned enrollment
4th of 16
330 · median 66
Started
2018
with 2 others
Phase 3
3 of 16
none open now
Registered
14th of 16
by date
Lead sponsor
1 of 16
University College, London

Among the 16 studies testing cediranib in Ovarian Neoplasms, this one is the 4th largest by planned enrollment, is one of 3 that started in 2018, is one of 3 in phase 3, and was the 14th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

None of the 16 studies testing cediranib in Ovarian Neoplasms is open now. The open studies under Ovarian Neoplasms, anywhere →

About cediranib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing cediranib in Ovarian Neoplasms as a file.
02

Study summary

ICON 9 will assess the efficacy, safety and tolerability of maintenance olaparib in combination with cediranib compared to maintenance olaparib alone following a response to platinum-based chemotherapy in women with relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer. Prognostic and predictive factors will be studied from tumour and blood samples.

Read the detailed description

ICON9 is an international multicentre randomised, phase III trial assessing maintenance treatment with olaparib and cediranib or olaparib alone in women with relapsed ovarian cancer whose disease progressed more than 6 months after first line chemotherapy. Women whose disease responds to platinum chemotherapy following 3 to 4 cycles can be registered for collection of germline BRCA test results if known, and somatic BRCA testing of archival tumour specimens or secondary debulking tissue if required. Patients who have completed treatment and whose disease has responded (partial or complete) to a minimum of 4 cycles of platinum based chemotherapy will be randomised to maintenance treatment of either olaparib and cediranib or olaparib alone.

The maintenance regimen may be continued beyond radiological progression until trial closure if the patient is deemed to still be deriving clinical benefit, but must be discontinued once subsequent treatment is instituted.

03

Conditions studied

  • Ovarian Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Registration Inclusion Criteria:

  1. Provision of prior to any study specific procedures and the ability to comply with the protocol for the duration of the study, including undergoing treatment and scheduled visits and examinations.
  2. Females aged ≥ 18 years with previous proven diagnosis of high grade serous or endometrioid carcinoma of the

    • Ovary
    • Fallopian tube
    • or peritoneum, progressing >6 months after day 1 of the last cycle of platinum-based chemotherapy and requiring treatment with platinum-based chemotherapy on the basis of radiological evidence of disease or following surgical resection of recurrent disease.
  3. Patients must have had CT or MRI proven disease (measureable or non-measureable abnormalities supported by GCIG CA125 criteria of progression), or have had debulking surgery for first relapse.
  4. Patients showing evidence of response to chemotherapy mid-treatment (post 3 or 4 cycles), either by CA125 or CT/MRI scan, should be approached for ICON9 trial registration to allow for BRCA mutation status to be assessed (germline and/ or somatic). Patients who underwent surgical debulking must show no evidence of disease progression by the assessments above (CA125 and CT/MRI scan) in order to be approached for registration.
  5. Prior front-line maintenance therapy with bevacizumab is permitted.
  6. performance status 0-1.
  7. Formalin fixed, paraffin embedded (FFPE) archival/diagnostic tumour sample or from secondary debulking surgery with adequate neoplastic cell content (>30%), must be available for central BRCA testing. For inclusion in i) the genetic HRD Test and ii) the biomarker research, patients must complete the consent form. Translational blood samples are also required, see Laboratory Manual for further details.
  8. Patients should have a ≥ 16 weeks.
  9. or evidence of non-childbearing status for women of : negative urine or serum pregnancy test within 28 days prior to study treatment and confirmed prior to treatment on day 1.

    Postmenopausal is defined as age ≥60 years, or:

    • Amenorrheic for 1 year or more following cessation of exogenous hormonal treatments
    • Luteinizing hormone (LH) and Follicle stimulating hormone (FSH) levels in the post-menopausal range for women under 50
    • Radiation-induced oophorectomy with last menses >1 year ago
    • Chemotherapy-induced menopause with >1 year interval since last menses
    • Surgical sterilisation (bilateral oophorectomy or hysterectomy)
  10. Adequately controlled blood pressure (systolic blood pressure [SBP] ≤140 mmHg; diastolic blood pressure [DBP] ≤ 90mmHg) on maximum of 2 antihypertensive medications.
  11. Adequately controlled thyroid function, with no symptoms of thyroid dysfunction.

Randomisation Inclusion Criteria:

  1. Patients must have received at least 4 cycles, and a maximum of 6 cycles of second-line platinum-based chemotherapy.
  2. In patients with , end of treatment scans must have a v1.1 'partial response' or 'complete response' and meet one of the following CA125 requirements:

    1. If the first screening CA125 value is below the the patient is eligible for randomisation and a second CA125 assessment is not required.
    2. If the first screening CA125 value is greater than ULN then a second assessment is required at least 7 days after the first to confirm eligibility. If the second CA125 value has risen by ≥ 15% then the patient will not be eligible.
  3. In patients with non-measurable disease, who have not undergone debulking surgery, they must have had a GCIG CA125 response to chemotherapy and meet one of the following CA125 requirements:

    1. If the first screening CA125 value is below the ULN the patient is eligible for randomisation and a second CA125 assessment is not required.
    2. If the first screening CA125 value is greater than ULN then a second assessment is required at least 7 days after the first to confirm eligibility. If the second CA125 value has risen by ≥ 15% then the patient will not be eligible.
  4. Patients who have had debulking surgery at first relapse must have no evidence of disease progression on imaging (CT or MRI) and meet one of the following CA125 requirements:

    1. If the first screening CA125 value is below the ULN the patient is eligible for randomisation and a second CA125 assessment is not required.
    2. If the first screening CA125 value is greater than ULN then a second assessment is required at least 7 days after the first to confirm eligibility. If the second CA125 value has risen by ≥ 15% then the patient will not be eligible.
  5. Expected to be able to commence treatment within 7 days post randomisation, and within 4-8 weeks post day 1 of the last cycle of chemotherapy.
  6. Adequate bone marrow function as defined below:

    • (ANC) ≥ 1.5 x 109/l
    • (Plt) ≥ 90 x 109/l
    • (Hb) ≥ 100g/l required and no packed blood transfusions in the 14 days prior to starting trial treatment
  7. Adequate liver function as defined below:

    • Serum ≤ 1.5 x ULN (or ≤ 3 for cases of known Gilbert's syndrome)
    • Serum transaminases ≤3 x ULN
    • Serum transaminases ≤ 5 x ULN if liver present
  8. Adequate renal function as defined below:

    • Serum creatinine ≤ 1.5 x ULN and calculated (GFR) ≥50ml/min (calculated as per local practice using Wright or Cockroft-gault formula)
  9. Urine dipstick for proteinuria \<2+. If urine dipstick is ≥ 2+ on two occasions more than one week apart then a 24-hour urine must demonstrate ≤ 1 g of protein in 24 hours or protein/creatinine ratio \< 1.5.
  10. Adequately controlled blood pressure (systolic blood pressure [SBP] ≤140 mmHg; diastolic blood pressure [DBP] ≤ 90mmHg) on maximum of 2 antihypertensive medications.
  11. Germline and/or somatic BRCA mutation status must be known prior to randomisation.

Exclusion Criteria:

  1. Non-epithelial ovarian cancer, carcinosarcoma, clear cell carcinoma and mucinous carcinomas.
  2. Arterial thrombotic event (including , cerebrovascular accident, and peripheral arterial embolus) within the last 12 months.
  3. Patients unable to swallow orally administered medication and patients with gastrointestinal impairment that could affect ability to take, or absorption of oral medicines including sub-acute or complete bowel obstruction.
  4. signs and/or symptoms of bowel obstruction within 3 months prior to starting treatment.
  5. History of intra-abdominal abscess within 3 months prior to starting treatment (randomisation).
  6. History of GI perforation. Patients with a history of abdominal fistula will be considered eligible if the fistula was surgically repaired, there has been no evidence of fistula for at least 6 months prior to starting treatment, and patient is deemed to be at low risk of recurrent fistula.
  7. Symptomatic or clinically significant inflammatory bowel disease (Crohn's disease or ulcerative colitis).
  8. Patients with an ileostomy will be excluded.
  9. Evidence of severe or uncontrolled cardiac disease.

    1. Myocardial infarct or unstable angina within the last 6 months
    2. New York Health Association (NHYA) ≥ grade 2 congestive heart failure
    3. Cardiac ventricular arrhythmias requiring medication
    4. History of 2nd or 3rd degree atrioventricular conduction defects
  10. Resting with > 470msec on 2 or more time points within a 24 hour period or family history of long QT syndrome.
  11. Evidence of active bleeding or bleeding diathesis.

    Significant haemorrhage of >30ml in a single episode within the last 3 months or any haemoptysis (>5ml fresh blood in last 4 weeks).

  12. treated within the last 5 years except: adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, ductal carcinoma in situ (DCIS) of the breast, Stage 1, grade 1 endometrial carcinoma.
  13. Previous treatment with VEGFR tyrosine kinase inhibitors or PARP inhibitors are not permitted.
  14. Patients with a known to of cediranib or olaparib.
  15. Persisting ≥ grade 2 toxicity (except alopecia and neuropathy) from previous anti-cancer treatment.
  16. Major surgery within 14 days before anticipated start of treatment and patients must have recovered from any effects of major surgery.
  17. Inability to attend or comply with treatment or follow-up scheduling.
  18. Evidence of any other disease, metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that the use of an investigation drug or puts the patients at high risk for treatment-related complications.
  19. Pregnant or breast-feeding women are excluded. Women of childbearing potential will be excluded unless effective methods of are used from signing of the informed consent, throughout the period of taking study treatment and for at least 6 weeks after last dose of trial drug(s).
  20. Treatment with any other agent, or participation in another interventional clinical trial within 28 days prior to enrolment (randomisation).
  21. Concomitant use of known strong inhibitors (such as systemic ketoconazole, itraconazole, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir, telithromycin and clarithromycin or moderate CYP3A inhibitors (e.g. systemic Ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required prior to starting olaparib is 2 weeks.
  22. Concomitant use of known strong (e.g. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or moderate CYP3A inducers (eg. bosentan, efavirenz, modafinil). The required washout period prior to starting olaparib is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents.
  23. Patients with myelodysplastic syndrome/acute myeloid leukaemia.
  24. Other psychological, psychiatric, social or medical condition, physical examination finding or a laboratory abnormality that the Investigator considers would make the patient a poor trial candidate or could interfere with protocol compliance or the interpretation of trial results.
  25. Patients with known active hepatitis (i.e. or C) due to risk of transmitting the infection through blood or other body fluids.
  26. patients e.g., patients who are known to be serologically positive for (HIV) and are receiving antiviral therapy.
  27. Patients with symptomatic uncontrolled brain or meningeal metastases. A scan to confirm the absence of is not required. The patient can receive a stable dose of before and during the study as long as these were started at least 4 weeks prior to treatment.
  28. Patients with spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease for 28 days.
  29. Previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT).
Terms in these criteria, in plain language(35)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
330 participants (estimated)

Study arms

  • Experimental
    Olaparib and Cediranib

    Patients will receive oral olaparib 300mg BD and oral cediranib 20mg OD. Patients will attend hospital for a 2 weekly review for the first 8 weeks, then 4 weekly for year 1 and 8 weekly for year 2 onwards until discontinuation of all trial drugs. Treatment may continue beyond progression until the next line of treatment if the patient is deemed to still be deriving clinical benefit. QOL instruments will be collected at baseline, every clinic visit and continue to be completed after relapse.

    Drug: Olaparib · Drug: Cediranib

  • Active comparator
    Olaparib

    Patients will receive oral olaparib 300mg BD. Patients will attend hospital for a 2 weekly review for the first 8 weeks, then 4 weekly for year 1 and 8 weekly for year 2 onwards until discontinuation of all trial drugs. Treatment may continue beyond progression until the next line of treatment if the patient is deemed to still be deriving clinical benefit. QOL instruments will be collected at baseline, every clinic visit and continue to be completed after relapse.

    Drug: Olaparib

Interventions

  • Olaparib is a PARP inhibitor, targeting DNA repair processes.

  • Cediranib is an inhibitor of vascular endothelial growth factor-A (VEGF), targeting angiogenesis.

06

What researchers measure

Primary outcomes

  1. Progression free survival (PFS) measured from the date of randomisation to the date of objective progression (investigator assessed using RECIST v1.1) or date of death from any cause (in the absence of progression)

    Progression free survival (PFS) measured from the time of randomisation.

    Time frame: 3 years

Secondary outcomes

  1. Toxicity

    Toxicity (AEs) experienced by patients as assessed by the Common Terminology Criteria for Adverse Events v4.03

    Time frame: 3 years

  2. PFS and OS measured from the time of starting chemotherapy

    PFS and OS measured from the time of starting chemotherapy

    Time frame: 3 years

  3. Adherence to maintenance therapy- compliance and dose reductions and interruptions

    Adherence to maintenance therapy- compliance and dose reductions and interruptions

    Time frame: 3 years

  4. TSST (the time from randomisation to start of second subsequent therapy or death)

    TSST (the time from randomisation to start of second subsequent therapy or death)

    Time frame: 3 years

  5. Quality of life using EORTC QLQ C30

    Quality of life using EORTC QLQ C30

    Time frame: 3 years

  6. Quality of life using EORTC QLQ OV28

    Quality of life using EORTC QLQ OV28

    Time frame: 3 years

  7. Cost effectiveness using EQ-5D-5L for economic evaluation

    Cost effectiveness using EQ-5D-5L for economic evaluation

    Time frame: 3 years

  8. VIII. Response rate (RECIST v1.1 and/or CA125) at 16 weeks of treatment in patients who had RECIST v1.1 measurable disease or elevated CA125 at randomisation. RECIST measurements will be based on investigator assessment not central review

    VIII. Response rate (RECIST v1.1 and/or CA125) at 16 weeks of treatment in patients who had RECIST v1.1 measurable disease or elevated CA125 at randomisation. RECIST measurements will be based on investigator assessment not central review

    Time frame: 3 years

  9. Overall survival (OS) measured from the date of randomisation to the date of death from any cause

    Overall survival (death from any cause) measured from the time of randomisation.

    Time frame: 3 years

07

Study locations

52 of 54 sites recruiting
  • Calvary Mater Hospital
    Sydney, New South Wales, Australia
    Recruiting
    • Janine Lombard · Principal investigator
  • Campbelltown Hospital
    Sydney, New South Wales, Australia
    Recruiting
    • Felicia Roncolato · Principal investigator
  • Prince of Wales Hospital
    Sydney, New South Wales, Australia
    Recruiting
    • Michael Friedlander · Principal investigator
  • Royal Hobart Hospital
    Hobart, Tasmania, Australia
    Recruiting
    • Allison Black · Principal investigator
  • Border Medical Oncology
    Albury, Australia
    Recruiting
    • Christopher Steer · Principal investigator
  • Flinders Medical Centre
    Bedford Park, Australia
    Recruiting
    • Ganessan Kichenadasse · Principal investigator
  • Pindara Private Hospital
    Benowa, Australia
    Recruiting
    • Marco Matos · Principal investigator
  • Chris O'Brien Lifehouse
    Camperdown, Australia
    Recruiting
    • Michelle Harrison · Principal investigator
  • Canberra Hospital
    Canberra, Australia
    Recruiting
    • Alison Davies · Principal investigator
  • Monash Health
    Clayton, Australia
    Recruiting
    • Kate Webber · Principal investigator
  • Gosford Hospital
    Gosford, Australia
    Recruiting
    • Craig Kukard · Principal investigator
  • Peter MacCallum Cancer Centre
    Melbourne, Australia
    Recruiting
    • Linda Mileshkin · Principal investigator
  • ICON Cancer Centre
    South Brisbane, Australia
    Recruiting
    • Jim Coward · Principal investigator
  • Mater Cancer Centre
    South Brisbane, Australia
    Recruiting
    • Catherine Shannon · Principal investigator
  • Townsville Hospital
    Townsville, Australia
    Recruiting
    • Abhishek Joshi · Principal investigator
  • Westmead Hospital
    Westmead, Australia
    Recruiting
    • Paul Harnett · Principal investigator
  • Cross Cancer Institute
    Edmonton, Canada
    Recruiting
    • Michael Kolinsky · Principal investigator
  • Centre Hospitalier de L'Universite de Montreal
    Montréal, Canada
    Recruiting
    • Diane Provencher · Principal investigator
  • CHU de Quebec
    Québec, Canada
    Recruiting
    • Vincent Castonguay · Principal investigator
  • Princess Margaret Cancer Centre
    Toronto, Canada
    Recruiting
    • Stephanie Lheureux · Principal investigator
  • Sunnybrook Hospital
    Toronto, Canada
    Recruiting
    • Helen MacKay · Principal investigator
  • BC Cancer Vancouver
    Vancouver, Canada
    Recruiting
    • Anna Tinker · Principal investigator
  • BC Cancer Victoria
    Victoria, Canada
    Recruiting
    • Jennifer Rauw · Principal investigator
  • Auckland City Hospital
    Auckland, New Zealand
    Recruiting
    • Michelle Wilson · Principal investigator
  • Christchurch Hospital
    Christchurch, New Zealand
    Recruiting
    • Michelle Vaughan · Principal investigator
  • Furness General Hospital
    Barrow In Furness, United Kingdom
    Recruiting
    • Sarah Moon · Principal investigator
  • Belfast City Hospital
    Belfast, United Kingdom
    Terminated
  • Royal Sussex County Hospital
    Brighton, United Kingdom
    Recruiting
    • Rebecca Herbertson · Principal investigator
  • Addenbrookes Hospital
    Cambridge, United Kingdom
    Recruiting
    • Joo Ern Ang · Principal investigator
  • Kent & Canterbury Hospital
    Canterbury, United Kingdom
    Recruiting
    • Justin Waters · Principal investigator
  • Velindre Cancer Centre
    Cardiff, United Kingdom
    Recruiting
    • Louise Hanna · Principal investigator
  • Cheltenham General Hospital
    Cheltenham, United Kingdom
    Recruiting
    • Audrey Cook · Principal investigator
  • University Hospital Coventry
    Coventry, United Kingdom
    Recruiting
    • Lucy McAven · Principal investigator
  • Ninewells Hospital
    Dundee, United Kingdom
    Recruiting
    • Michelle Ferguson · Principal investigator
  • Western General Hospital
    Edinburgh, United Kingdom
    Recruiting
    • Charlie Gourley · Principal investigator
  • Beatson West of Scotland Cancer Centre
    Glasgow, United Kingdom
    Recruiting
    • Ros Glasspool · Principal investigator
  • Royal Surrey County Hospital
    Guildford, United Kingdom
    Recruiting
    • Agnieszka Michael · Principal investigator
  • Royal Lancaster Infirmary
    Lancaster, United Kingdom
    Recruiting
    • Sarah Moon · Principal investigator
  • Guy's Hospital
    London, United Kingdom
    Recruiting
    • Ana Montes · Principal investigator
  • Hammersmith Hospital
    London, United Kingdom
    Recruiting
    • Laura Tookman · Principal investigator
  • Mount Vernon Cancer Centre
    London, United Kingdom
    Recruiting
    • Ignacio Vazquez · Principal investigator
  • Royal Marsden NHS Foundation Trust
    London, United Kingdom
    Recruiting
    • Susanna Banerjee · Principal investigator
  • University College London Hospital
    London, United Kingdom
    Recruiting
    • Jonathan Ledermann · Principal investigator
  • The Christie Hospital
    Manchester, United Kingdom
    Recruiting
    • Gordon Jayson · Principal investigator
  • Queen Elizabeth the Queen Mother Hospital
    Margate, United Kingdom
    Recruiting
    • Justin Waters · Principal investigator
  • Churchill Hospital
    Oxford, United Kingdom
    Recruiting
    • Shibani Nicum · Principal investigator
  • Queen Alexandra Hospital
    Portsmouth, United Kingdom
    Active, not recruiting
  • Royal Berkshire Hospital
    Reading, United Kingdom
    Recruiting
    • Madhumita Battacharyya · Principal investigator
  • Southampton General Hospital
    Southampton, United Kingdom
    Recruiting
    • Clare Green · Principal investigator
  • Lister Hospital
    Stevenage, United Kingdom
    Recruiting
    • Ignacio Vazquez · Principal investigator
  • Singleton Hospital
    Swansea, United Kingdom
    Recruiting
    • Rachel Jones · Principal investigator
  • Musgrove Park Hospital
    Taunton, United Kingdom
    Recruiting
    • Emma Cattell · Principal investigator
  • Royal Cornwall
    Truro, United Kingdom
    Recruiting
    • John McGrane · Principal investigator
  • Clatterbridge Cancer Centre
    Wirral, United Kingdom
    Recruiting
    • Danielle Shaw · Principal investigator
08

References and documents

Publications

  • Elyashiv O, Ledermann J, Parmar G, Farrelly L, Counsell N, Feeney A, El-Khouly F, Macdonald I, Neto A, Arthur-Darkwa E, Burnett E, Jayson GC, Mileshkin L, Gourley C, Nicum S. ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy. Int J Gynecol Cancer. 2021 Jan;31(1):134-138. doi: 10.1136/ijgc-2020-002073. Epub 2020 Oct 23. PubMed 33097567 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2018 (actual). Primary completion is estimated for Dec 2023, 66 months after the start.

Of 52 non-industry phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 115. This study's planned 66 months is below that.

Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2017
First posted
Sep 12, 2017
StartActual
Jun 15, 2018
Primary completionEst.
Dec 2023
CompletionEst.
Dec 2023
Last update
Sep 27, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 27, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03278717
Responsible party
Sponsor
First posted
Sep 12, 2017
Start date
Jun 15, 2018
Primary completion
Dec 2023 (estimated)
Completion
Dec 2023 (estimated)
Last update
Sep 27, 2022

Study contacts

Ian Macdonald
Contact
ctc.ICON9@ucl.ac.uk
+44 (0)20 7679 9808
Mandy Feeney
Contact
ctc.ICON9@ucl.ac.uk
+44 (0)20 7679 9890

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cediranib

Start the discussion